Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database
Overview
Paper Summary
This study found JAK inhibitors were associated with increased reporting of infections, embolism/thrombosis, neoplasms, and gastrointestinal perforations. While some of these were already known, it raises further concerns about malignancies and gastrointestinal issues, though major cardiovascular events were not significantly associated.
Explain Like I'm Five
Scientists found that some medicines, called JAK inhibitors, were linked to people getting more infections, blood clots, cancer, or even tiny holes in their stomach. It's like these medicines might sometimes cause other problems.
Possible Conflicts of Interest
Aurelien Amiot received consulting fees and travel accommodations from Pfizer. Pascal Claudepierre reported receiving personal fees from Abbvie, Pfizer, Roche-Chugai Bristol-Myers Squibb, MSD, UCB, Novartis, Janssen, Lilly, Celgene.
Identified Limitations
Rating Explanation
The study provides valuable insights into the safety profile of JAK inhibitors using a large pharmacovigilance database. However, several methodological limitations, including under-reporting, lack of case-causality assessment, and missing data, prevent stronger conclusions. The identified conflicts of interest also warrant consideration.
Good to know
This is the Starter analysis. Paperzilla Pro fact-checks every citation, researches author backgrounds and funding sources, and uses advanced AI reasoning for more thorough insights.
Explore Pro →